Shopping Cart 0
Cart Subtotal
AED 0

CRISPR Therapeutics AG - Strategy, SWOT and Corporate Finance Report

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 642

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1285

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1927

Details

CRISPR Therapeutics AG-Strategy, SWOT and Corporate Finance Report

Summary

CRISPR Therapeutics AG-Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Key Highlights

CRISPR Therapeutics AG (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes or corrects disease-causing abnormalities at their genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Basel, Switzerland.

Scope

- Detailed information on CRISPR Therapeutics AG required for business and competitor intelligence needs

- A study of the major internal and external factors affecting CRISPR Therapeutics AG in the form of a SWOT analysis

- An in-depth view of the business model of CRISPR Therapeutics AG including a breakdown and examination of key business segments

- Intelligence on CRISPR Therapeutics AG's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about CRISPR Therapeutics AG, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of CRISPR Therapeutics AG and the factors that influence its strategies.

- Track strategic initiatives of the company and latest corporate news and actions.

- Assess CRISPR Therapeutics AG as a prospective partner, vendor or supplier.

- Support sales activities by understanding your customers' businesses better.

- Stay up to date on CRISPR Therapeutics AG's business structure, strategy and prospects.

READ MORE

Table Of Content

Scope

Table of Contents

Company Snapshot

Table of Contents

CRISPR Therapeutics AG: Company Overview

CRISPR Therapeutics AG: Overview and Key Facts

CRISPR Therapeutics AG: Overview

CRISPR Therapeutics AG: Key Facts

CRISPR Therapeutics AG: Key Employees

CRISPR Therapeutics AG: Key Employee Biographies

CRISPR Therapeutics AG: Major Products and Services

CRISPR Therapeutics AG: Company History

CRISPR Therapeutics AG: Management Statement

CRISPR Therapeutics AG: Key Competitors

CRISPR Therapeutics AG: Company Analysis

CRISPR Therapeutics AG: Business Description

CRISPR Therapeutics AG: SWOT Analysis

CRISPR Therapeutics AG: SWOT Overview

CRISPR Therapeutics AG: Strengths

CRISPR Therapeutics AG: Weaknesses

CRISPR Therapeutics AG: Opportunities

CRISPR Therapeutics AG: Threats

CRISPR Therapeutics AG: Corporate Financial Deals Activity

CRISPR Therapeutics AG: Financial Deals Overview

CRISPR Therapeutics AG: Targets and Partners

CRISPR Therapeutics AG: Top Deals 2015-2019YTD*

CRISPR Therapeutics AG: Advisors

CRISPR Therapeutics AG: Top Legal Advisors

CRISPR Therapeutics AG: Top Financial Advisors

CRISPR Therapeutics AG: Capital Raising

CRISPR Therapeutics AG: Partnership

CRISPR Therapeutics AG: Private Equity and Ownership

CRISPR Therapeutics AG: Recent Developments

CRISPR Therapeutics AG: News and Events Summary

CRISPR Therapeutics AG: Business Expansion

CRISPR Therapeutics AG: Corporate Governance

CRISPR Therapeutics AG: Financial Deals

CRISPR Therapeutics AG: Financial Performance

CRISPR Therapeutics AG: Grants

CRISPR Therapeutics AG: Market Developments

CRISPR Therapeutics AG: Research & Development

Appendix

Contact Us

Methodology

About MarketLine


List Of Figure

List of Figures

Figure 1: CRISPR Therapeutics AG: Deal Activity by Deal Type-Volume (TTM*)

Figure 2: CRISPR Therapeutics AG: Deal Activity by Deal Type-Volume (2015-YTD*2019)

Figure 3: CRISPR Therapeutics AG: Capital Raising Volume and Value Trend (2015-YTD*2019)

Figure 4: CRISPR Therapeutics AG: Capital Raising by Deal Type (2015-YTD*2019)

Figure 5: CRISPR Therapeutics AG: Partnership Volume and Value Trend (2015-YTD*2019)

Figure 6: CRISPR Therapeutics AG: Partnership Trend by Deal Type (2015-YTD*2019)

Figure 7: CRISPR Therapeutics AG: Private Equity and Ownership Volume and Value Trend (2015-YTD*2019)

Figure 8: CRISPR Therapeutics AG: Private Equity and Ownership Volume by Deal Type (2015-YTD*2019)


List Of Table

List of Tables

Table 1: CRISPR Therapeutics AG: Key Facts

Table 2: CRISPR Therapeutics AG: Key Employees

Table 3: CRISPR Therapeutics AG: Company History

Table 4: CRISPR Therapeutics AG: Key Competitors

Table 5: CRISPR Therapeutics AG: Deal Activity by Deal Type-Volume (TTM*)

Table 6: CRISPR Therapeutics AG: Deal Activity by Deal Type-Volume (2015-YTD*2019)

Table 7: CRISPR Therapeutics AG: Targets and Partners

Table 8: CRISPR Therapeutics AG: Top Deals 2015-2019YTD*

Table 9: CRISPR Therapeutics AG: Legal Advisor Ranking by Value (USD m)

Table 10: CRISPR Therapeutics AG: Financial Advisor Ranking by Value (USD m)

Table 11: CRISPR Therapeutics AG: Capital Raising Volume and Value Trend (2015-YTD*2019)

Table 12: CRISPR Therapeutics AG: Capital Raising by Deal Type (2015-YTD*2019)

Table 13: CRISPR Therapeutics AG: Partnership Volume and Value Trend (2015-YTD*2019)

Table 14: CRISPR Therapeutics AG: Partnership Trend by Deal Type (2015-YTD*2019)

Table 15: CRISPR Therapeutics AG: Private Equity and Ownership Volume and Value Trend (2015-YTD*2019)

Table 16: CRISPR Therapeutics AG: Private Equity and Ownership Volume by Deal Type (2015-YTD*2019)

Table 17: CRISPR Therapeutics AG: News and Events Summary

Table 18: CRISPR Therapeutics AG: Business Expansion

Table 19: CRISPR Therapeutics AG: Corporate Governance

Table 20: CRISPR Therapeutics AG: Financial Deals

Table 21: CRISPR Therapeutics AG: Financial Performance

Table 22: CRISPR Therapeutics AG: Grants

Table 23: CRISPR Therapeutics AG: Market Developments

Table 24: CRISPR Therapeutics AG: Research & Development

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

CRISPR Therapeutics AG-Strategy, SWOT and Corporate Finance Report

Summary

CRISPR Therapeutics AG-Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Key Highlights

CRISPR Therapeutics AG (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes or corrects disease-causing abnormalities at their genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Basel, Switzerland.

Scope

- Detailed information on CRISPR Therapeutics AG required for business and competitor intelligence needs

- A study of the major internal and external factors affecting CRISPR Therapeutics AG in the form of a SWOT analysis

- An in-depth view of the business model of CRISPR Therapeutics AG including a breakdown and examination of key business segments

- Intelligence on CRISPR Therapeutics AG's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about CRISPR Therapeutics AG, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of CRISPR Therapeutics AG and the factors that influence its strategies.

- Track strategic initiatives of the company and latest corporate news and actions.

- Assess CRISPR Therapeutics AG as a prospective partner, vendor or supplier.

- Support sales activities by understanding your customers' businesses better.

- Stay up to date on CRISPR Therapeutics AG's business structure, strategy and prospects.

READ MORE

Scope

Table of Contents

Company Snapshot

Table of Contents

CRISPR Therapeutics AG: Company Overview

CRISPR Therapeutics AG: Overview and Key Facts

CRISPR Therapeutics AG: Overview

CRISPR Therapeutics AG: Key Facts

CRISPR Therapeutics AG: Key Employees

CRISPR Therapeutics AG: Key Employee Biographies

CRISPR Therapeutics AG: Major Products and Services

CRISPR Therapeutics AG: Company History

CRISPR Therapeutics AG: Management Statement

CRISPR Therapeutics AG: Key Competitors

CRISPR Therapeutics AG: Company Analysis

CRISPR Therapeutics AG: Business Description

CRISPR Therapeutics AG: SWOT Analysis

CRISPR Therapeutics AG: SWOT Overview

CRISPR Therapeutics AG: Strengths

CRISPR Therapeutics AG: Weaknesses

CRISPR Therapeutics AG: Opportunities

CRISPR Therapeutics AG: Threats

CRISPR Therapeutics AG: Corporate Financial Deals Activity

CRISPR Therapeutics AG: Financial Deals Overview

CRISPR Therapeutics AG: Targets and Partners

CRISPR Therapeutics AG: Top Deals 2015-2019YTD*

CRISPR Therapeutics AG: Advisors

CRISPR Therapeutics AG: Top Legal Advisors

CRISPR Therapeutics AG: Top Financial Advisors

CRISPR Therapeutics AG: Capital Raising

CRISPR Therapeutics AG: Partnership

CRISPR Therapeutics AG: Private Equity and Ownership

CRISPR Therapeutics AG: Recent Developments

CRISPR Therapeutics AG: News and Events Summary

CRISPR Therapeutics AG: Business Expansion

CRISPR Therapeutics AG: Corporate Governance

CRISPR Therapeutics AG: Financial Deals

CRISPR Therapeutics AG: Financial Performance

CRISPR Therapeutics AG: Grants

CRISPR Therapeutics AG: Market Developments

CRISPR Therapeutics AG: Research & Development

Appendix

Contact Us

Methodology

About MarketLine


List Of Figure

List of Figures

Figure 1: CRISPR Therapeutics AG: Deal Activity by Deal Type-Volume (TTM*)

Figure 2: CRISPR Therapeutics AG: Deal Activity by Deal Type-Volume (2015-YTD*2019)

Figure 3: CRISPR Therapeutics AG: Capital Raising Volume and Value Trend (2015-YTD*2019)

Figure 4: CRISPR Therapeutics AG: Capital Raising by Deal Type (2015-YTD*2019)

Figure 5: CRISPR Therapeutics AG: Partnership Volume and Value Trend (2015-YTD*2019)

Figure 6: CRISPR Therapeutics AG: Partnership Trend by Deal Type (2015-YTD*2019)

Figure 7: CRISPR Therapeutics AG: Private Equity and Ownership Volume and Value Trend (2015-YTD*2019)

Figure 8: CRISPR Therapeutics AG: Private Equity and Ownership Volume by Deal Type (2015-YTD*2019)


List Of Table

List of Tables

Table 1: CRISPR Therapeutics AG: Key Facts

Table 2: CRISPR Therapeutics AG: Key Employees

Table 3: CRISPR Therapeutics AG: Company History

Table 4: CRISPR Therapeutics AG: Key Competitors

Table 5: CRISPR Therapeutics AG: Deal Activity by Deal Type-Volume (TTM*)

Table 6: CRISPR Therapeutics AG: Deal Activity by Deal Type-Volume (2015-YTD*2019)

Table 7: CRISPR Therapeutics AG: Targets and Partners

Table 8: CRISPR Therapeutics AG: Top Deals 2015-2019YTD*

Table 9: CRISPR Therapeutics AG: Legal Advisor Ranking by Value (USD m)

Table 10: CRISPR Therapeutics AG: Financial Advisor Ranking by Value (USD m)

Table 11: CRISPR Therapeutics AG: Capital Raising Volume and Value Trend (2015-YTD*2019)

Table 12: CRISPR Therapeutics AG: Capital Raising by Deal Type (2015-YTD*2019)

Table 13: CRISPR Therapeutics AG: Partnership Volume and Value Trend (2015-YTD*2019)

Table 14: CRISPR Therapeutics AG: Partnership Trend by Deal Type (2015-YTD*2019)

Table 15: CRISPR Therapeutics AG: Private Equity and Ownership Volume and Value Trend (2015-YTD*2019)

Table 16: CRISPR Therapeutics AG: Private Equity and Ownership Volume by Deal Type (2015-YTD*2019)

Table 17: CRISPR Therapeutics AG: News and Events Summary

Table 18: CRISPR Therapeutics AG: Business Expansion

Table 19: CRISPR Therapeutics AG: Corporate Governance

Table 20: CRISPR Therapeutics AG: Financial Deals

Table 21: CRISPR Therapeutics AG: Financial Performance

Table 22: CRISPR Therapeutics AG: Grants

Table 23: CRISPR Therapeutics AG: Market Developments

Table 24: CRISPR Therapeutics AG: Research & Development

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS